ArticleCancer immunology, immunotherapy : CII2021

A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).

J Chandra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.